SCHEMBL84516

SCHEMBL84516

CC(C)c1ccc(S(N)(=O)=O)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 14/20 0.68
CA1 P00915 11/20 0.68
CA9 Q16790 10/20 0.68
CA12 O43570 10/20 0.68
ALDH1A1 P00352 3/20 0.64
CA7 P43166 6/20 0.58
CA5A P35218 5/20 0.58
CA5B Q9Y2D0 5/20 0.58
CA6 P23280 3/20 0.58
CA14 Q9ULX7 3/20 0.58
CA4 P22748 2/20 0.58
CA13 Q8N1Q1 2/20 0.58
USP2 O75604 1/20 0.58
TSHR P16473 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
AGO2 Q9UKV8 1/20 0.58
CA3 P07451 2/20 0.56
KDM4E B2RXH2 1/20 0.55
LMNA P02545 1/20 0.55
GAA P10253 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9423733 0.98 CA2 (0.66) CA2CA1CA9CA12ALDH1A1
Hydrochloric Acid SCHEMBL3532247 0.98 CA2 (0.66) CA2CA1CA9CA12ALDH1A1
Fluoride SCHEMBL28353367 0.98 CA2 (0.66) CA2CA1CA9CA12ALDH1A1
Benzenesulfonamide SCHEMBL9819524 0.85 CA2 (0.67) CA2CA1CA9CA12ALDH1A1
Sulfanilamide SCHEMBL27568655 0.84 CA2 (0.63) CA2CA1CA9CA12ALDH1A1
SCHEMBL8248221 0.84 ALDH1A1 (0.62) CA2CA1CA9CA12ALDH1A1
SCHEMBL1186051 0.84 ALDH1A1 (0.62) CA2CA1CA9CA12ALDH1A1
SCHEMBL1790668 0.84 ALDH1A1 (0.62) CA2CA1CA9CA12ALDH1A1
SCHEMBL672750 0.82 CA2 (1.00) CA2CA1CA9CA12CA7
SCHEMBL12112205 0.82 ALDH1A1 (0.60) CA2CA1CA9CA12ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 398 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119233829-A Pharmaceutical composition for preventing, inhibiting or treating symptoms associated with pseudoallergy 学校法人高崎健康福祉大学 2024-12-31 CN claimed
CN-118176003-A Medicaments comprising P2X4 receptor antagonists for the prevention or treatment of nociceptive pain and/or visceral pain 日本化学药品株式会社 2024-06-11 CN claimed
CN-118019551-A Preventive or therapeutic agent for respiratory diseases 日本化学药品株式会社 2024-05-10 CN claimed
CN-115942938-A Medicine for preventing or treating irritable bowel syndrome or inflammatory bowel disease 比萨大学 2023-04-07 CN claimed
CN-108928879-B Electroplating sewage treatment agent and preparation method thereof 江苏艾特克环境工程有限公司 2021-04-13 CN claimed
US-10201957-B2 Dye receiving layer composition, dye receiving substrate and method of fabricating the same CHIEN HWA COATING TECHNOLOGY , INC. (TW) 2019-02-12 US claimed
CN-108440856-A Dye-colored body and method for producing same 谦华科技股份有限公司 2018-08-24 CN claimed
EP-3363650-A1 DYE RECEIVING LAYER COMPOSITION, DYE RECEIVING SUBSTRATE AND METHOD OF FABRICATING THE SAME Chien Hwa Coating Technology, Inc. (TW) 2018-08-22 EP claimed
CN-101709045-B Preparation method of thiophenol UNIV ZHEJIANG 2013-02-27 CN claimed
WO-2011021216-A2 IMPROVED PROCESS FOR THE PREPARATION OF 4-(1,1-DIMETHYLETHYL)-N-[6-(2-HYDROXYETHOXY)-5-(2-METHOXYPHENOXY)[2,2'-BIPYRIMIDIN]-4-YL]BENZENESULFONAMIDE MSN LABORATORIES LIMITED (IN) 2011-02-24 WO claimed
CN-101709045-A Preparation method of thiophenol UNIV ZHEJIANG 2010-05-19 CN claimed
EP-2097414-A1 PYRROLO [2, 3-B]PYRIDINE DERIVATIVES AS KINASE MODULATORS PLEXXIKON, INC. (US) 2009-09-09 EP claimed
WO-2008079906-A1 PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS KINASE MODULATORS PLEXXIKON, INC. (US) 2008-07-03 WO claimed
US-12458624-B2 Deuterium-enriched substituted phenoxyphenyl acetic acids and acylsulfonamides DHANOA DALJIT SINGH (US) 2025-11-04 US disclosed
CN-119954725-A TEAD inhibitors and uses thereof 医肯纳肿瘤学公司 2025-05-09 CN disclosed
CN-119306668-A Benzimidazole compound, and preparation method and application thereof 中国医学科学院药物研究所 2025-01-14 CN disclosed
US-5270313-A Treatment of circulatory disorders HOFFMANN-LA ROCHE INC. (US) 1993-12-14 US disclosed
EP-0526708-A1 Sulfonamide, preparation and use thereof as medicine and intermediate F. HOFFMANN-LA ROCHE AG (CH) 1993-02-10 EP disclosed
EP-0510526-A1 Use of sulfonamides as drug and new sulfonamides F.HOFFMANN-LA ROCHE & CO. AKTIENGESELLSCHAFT (CH) 1992-10-28 EP disclosed
US-4168375-A Process for the recovery of cephalosporin C and derivatives thereof ALFA FARMACEUTICI, S.P.A. (IT) 1979-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12458624-B2 Deuterium-enriched substituted phenoxyphenyl acetic acids and acylsulfonamides AGTR2, AGTR1, EDNRA CA2 574/4885CA1 2870/4885CA9 2147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.